# A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty

> **NCT07710430** · PHASE4 · RECRUITING · sponsor: **LG Chem** · enrollment: 43 (estimated)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Leuprorelin

## Key facts

- **NCT ID:** NCT07710430
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-08-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710430, "A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*